Trial Profile
An Open-Label Phase 1 Study to Investigate the Safety and Efficacy of CYP-001 for the Treatment of Adults With Steroid-Resistant Acute Graft Versus Host Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Jan 2021
Price :
$35
*
At a glance
- Drugs CYP 001 (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- Sponsors Cynata Therapeutics
- 30 Jul 2020 According to a Cynata Therapeutics media release, study close-out procedures are now underway, which will include the preparation of a formal addendum to the clinical study report.
- 30 Jul 2020 Results from the two-year follow-up of patients enrolled in this study presented in a Cynata Therapeutics Media Release.
- 18 Dec 2019 According to a Cynata Therapeutics media release, clinical study report (CSR) describing full details of the results from this study has been completed.